Karin Havenith

1.2k total citations · 1 hit paper
40 papers, 829 citations indexed

About

Karin Havenith is a scholar working on Oncology, Molecular Biology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Karin Havenith has authored 40 papers receiving a total of 829 indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Oncology, 13 papers in Molecular Biology and 13 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Karin Havenith's work include CAR-T cell therapy research (23 papers), HER2/EGFR in Cancer Research (11 papers) and Lymphoma Diagnosis and Treatment (11 papers). Karin Havenith is often cited by papers focused on CAR-T cell therapy research (23 papers), HER2/EGFR in Cancer Research (11 papers) and Lymphoma Diagnosis and Treatment (11 papers). Karin Havenith collaborates with scholars based in United States, United Kingdom and Italy. Karin Havenith's co-authors include Jay Feingold, Mehdi Hamadani, Paolo F. Caimi, John Radford, Melhem Solh, David Ungar, Brad S. Kahl, Carmelo Carlo‐Stella, Kirit M. Ardeshna and Shui He and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Karin Havenith

37 papers receiving 818 citations

Hit Papers

Loncastuximab tesirine in relapsed or refractory diffuse ... 2021 2026 2022 2024 2021 50 100 150 200 250
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial
    2021 264 citations Paolo F. Caimi, Weiyun Z. Ai et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Karin Havenith United States 12 679 408 207 173 123 40 829
Florian Zettl Germany 9 612 0.9× 259 0.6× 317 1.5× 300 1.7× 106 0.9× 12 807
Cecilia Carpio Spain 15 388 0.6× 270 0.7× 62 0.3× 197 1.1× 200 1.6× 55 774
Julie A. McEarchern United States 13 537 0.8× 189 0.5× 294 1.4× 384 2.2× 132 1.1× 25 1.0k
Steven Park United States 14 282 0.4× 227 0.6× 55 0.3× 132 0.8× 121 1.0× 29 518
Magdalena Klánová Czechia 12 346 0.5× 397 1.0× 34 0.2× 130 0.8× 252 2.0× 38 721
Glenn Michelson United States 14 282 0.4× 136 0.3× 77 0.4× 112 0.6× 83 0.7× 51 668
Harm Westdorp Netherlands 14 439 0.6× 85 0.2× 102 0.5× 255 1.5× 36 0.3× 43 696
Lida Pacaud United States 12 520 0.8× 66 0.2× 84 0.4× 84 0.5× 51 0.4× 56 621
Scott A. Ezell United States 10 146 0.2× 121 0.3× 46 0.2× 76 0.4× 89 0.7× 11 552
Gregory E. Jones United States 8 463 0.7× 36 0.1× 350 1.7× 64 0.4× 36 0.3× 15 622

Countries citing papers authored by Karin Havenith

Since Specialization
Citations

This map shows the geographic impact of Karin Havenith's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Karin Havenith with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Karin Havenith more than expected).

Fields of papers citing papers by Karin Havenith

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Karin Havenith. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Karin Havenith. The network helps show where Karin Havenith may publish in the future.

Co-authorship network of co-authors of Karin Havenith

This figure shows the co-authorship network connecting the top 25 collaborators of Karin Havenith. A scholar is included among the top collaborators of Karin Havenith based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Karin Havenith. Karin Havenith is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Zammarchi, Francesca, Karin Havenith, Narinder Janghra, et al.. (2024). ADCT-602, a Novel PBD Dimer–containing Antibody–Drug Conjugate for Treating CD22-positive Hematologic Malignancies. Molecular Cancer Therapeutics. 23(4). 520–531. 6 indexed citations
2.
Yeung, Jenny, Aiyin Liao, Winston Vetharoy, et al.. (2024). Anti-CD45 PBD-based antibody-drug conjugates are effective targeted conditioning agents for gene therapy and stem cell transplant. Molecular Therapy. 32(6). 1672–1686. 6 indexed citations
3.
Horsley, Elizabeth, et al.. (2024). Abstract 3122: Preclinical development of a novel camptothecin-based antibody-drug conjugate targeting solid tumors expressing Claudin-6. Cancer Research. 84(6_Supplement). 3122–3122. 2 indexed citations
4.
Caimi, Paolo F., Mehdi Hamadani, Carmelo Carlo‐Stella, et al.. (2023). In relapsed or refractory diffuse large B‐cell lymphoma, CD19 expression by immunohistochemistry alone is not a predictor of response to loncastuximab tesirine. SHILAP Revista de lepidopterología. 5(1). 76–83. 2 indexed citations
5.
Zammarchi, Francesca, Karin Havenith, Veronica Gil, et al.. (2023). Abstract 2638: Preclinical development of ADCT-212, a PSMA-targeted antibody-drug conjugate employing the pyrrolobenzodiazepine dimer SG2000 for PSMA-expressing cancers. Cancer Research. 83(7_Supplement). 2638–2638. 2 indexed citations
6.
Wuerthner, Jens, Karin Havenith, Mehdi Hamadani, et al.. (2022). Population pharmacokinetics analysis of camidanlumab tesirine in patients with relapsed or refractory Hodgkin lymphoma and non-Hodgkin lymphoma. Cancer Chemotherapy and Pharmacology. 91(1). 13–24. 3 indexed citations
7.
Herrera, Alex F., Carmelo Carlo‐Stella, Pier Luigi Zinzani, et al.. (2022). CD25, Soluble CD25, and CCL17 As Potential Predictors of Clinical Response to Camidanlumab Tesirine in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma. Blood. 140(Supplement 1). 9306–9308. 2 indexed citations
8.
Hamadani, Mehdi, Graham P. Collins, Paolo F. Caimi, et al.. (2021). Camidanlumab tesirine in patients with relapsed or refractory lymphoma: a phase 1, open-label, multicentre, dose-escalation, dose-expansion study. The Lancet Haematology. 8(6). e433–e445. 63 indexed citations
9.
Caimi, Paolo F., Weiyun Z. Ai, Juan Pablo Alderuccio, et al.. (2021). Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial. The Lancet Oncology. 22(6). 790–800. 264 indexed citations breakdown →
10.
Depaus, Julien, Pier Luigi Zinzani, Tycel Phillips, et al.. (2021). CLINICAL ACTIVITY OF LONCASTUXIMAB TESIRINE PLUS IBRUTINIB IN NON‐HODGKIN LYMPHOMA: UPDATED LOTIS 3 PHASE 1 RESULTS. Hematological Oncology. 39(S2). 5 indexed citations
11.
Hamadani, Mehdi, John Radford, Carmelo Carlo‐Stella, et al.. (2020). Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma. Blood. 137(19). 2634–2645. 122 indexed citations
12.
Goldberg, Aaron D., Ehab Atallah, David A. Rizzieri, et al.. (2020). Camidanlumab tesirine, an antibody-drug conjugate, in relapsed/refractory CD25-positive acute myeloid leukemia or acute lymphoblastic leukemia: A phase I study. Leukemia Research. 95. 106385–106385. 27 indexed citations
13.
14.
15.
Kahl, Brad S., Mehdi Hamadani, John Radford, et al.. (2019). A Phase I Study of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody–Drug Conjugate, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma. Clinical Cancer Research. 25(23). 6986–6994. 77 indexed citations
16.
17.
18.
Horwitz, Steven M., Michelle A. Fanale, Karin Havenith, et al.. (2017). INTERIM DATA FROM THE FIRST CLINICAL STUDY OF ADCT‐301, A NOVEL PYRROLOBENZODIAZAPINE‐BASED ANTIBODY DRUG CONJUGATE, IN RELAPSED/REFRACTORY HODGKIN/NON‐HODGKIN LYMPHOMA. Hematological Oncology. 35(S2). 270–271. 8 indexed citations
19.
Zammarchi, Francesca, Simon Chivers, David G. Williams, et al.. (2016). ADCT-502, a novel pyrrolobenzodiazepine (PBD)-based antibody–drug conjugate (ADC) targeting low HER2-expressing solid cancers. European Journal of Cancer. 69. S28–S28. 14 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Florian Zettl Breakdown of academic impact, for papers by Cecilia Carpio Breakdown of academic impact, for papers by Julie A. McEarchern Breakdown of academic impact, for papers by Steven Park Breakdown of academic impact, for papers by Magdalena Klánová Breakdown of academic impact, for papers by Glenn Michelson Breakdown of academic impact, for papers by Harm Westdorp Breakdown of academic impact, for papers by Lida Pacaud Breakdown of academic impact, for papers by Scott A. Ezell Breakdown of academic impact, for papers by Gregory E. Jones
Rankless by CCL
2026